ValuEngine upgraded shares of CytRx Corporation (NASDAQ:CYTR) from a sell rating to a hold rating in a research report report published on Friday, July 28th.
Separately, HC Wainwright reissued a buy rating and set a $4.00 price objective on shares of CytRx Corporation in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. CytRx Corporation presently has a consensus rating of Hold and an average price target of $2.50.
Shares of CytRx Corporation (NASDAQ CYTR) traded down 4.155% during mid-day trading on Friday, hitting $0.549. The stock had a trading volume of 1,821,971 shares. The company has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.54. The firm’s market cap is $90.97 million. CytRx Corporation has a 12-month low of $0.36 and a 12-month high of $1.00.
Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in shares of CytRx Corporation during the first quarter valued at approximately $102,000. Hudson Bay Capital Management LP acquired a new stake in shares of CytRx Corporation during the fourth quarter valued at approximately $110,000. LMR Partners LLP acquired a new stake in shares of CytRx Corporation during the second quarter valued at approximately $235,000. Renaissance Technologies LLC acquired a new stake in shares of CytRx Corporation during the first quarter valued at approximately $264,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of CytRx Corporation by 795.0% in the second quarter. Goldman Sachs Group Inc. now owns 703,465 shares of the biotechnology company’s stock valued at $441,000 after buying an additional 624,863 shares during the period. 10.33% of the stock is owned by institutional investors and hedge funds.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
